Biotechnology News and Research

RSS

Research reveals new therapy for preventing production of sphingolipids by lymphoma cells

Christopher Parsons, MD, Director of the HIV Malignancies Program at LSU Health Sciences Center New Orleans, is the senior author of a paper that is the first to report that specialized fat (lipid) molecules, called sphingolipids, play a key role in the survival of aggressive lymphomas caused by viruses.

15 Jan 2014

Researchers discover two genetic mutations associated with Familial Alzheimer's Disease

New research, led by Rensselaer Polytechnic Institute researcher Chunyu Wang, has solved one mystery in the development of Familial Alzheimer's Disease (FAD), a genetic variant of the disease that affects a small fraction of the Alzheimer's population. In a paper published online January 6 in the journal Nature Communications, Wang and his team follow the trail of two genetic mutations - V44M and V44A - known to cause FAD, and show how the mutations lead to biochemical changes long linked to the disease.

13 Jan 2014

Life Technologies, Quest Diagnostics sign multi-year license and supply agreement

Life Technologies has completed a multi-year license and supply agreement with Quest Diagnostics, the world's leading provider of diagnostic information services, that gives Quest rights to develop molecular tests on the Ion Torrent next-generation sequencing platform. Under the agreement, Quest may use the platform and related consumables to independently develop new tests for numerous areas of their business.

From Quest Diagnostics 10 Jan 2014

Nottingham scientists use MRI technology to assist in treatment, diagnosis of irritable bowel syndrome

Scientists at The University of Nottingham are leading the world in exploiting MRI technology to assist in the treatment and diagnosis of Irritable Bowel Syndrome (IBS), a condition that causes serious inconvenience and discomfort to sufferers.

10 Jan 2014

Biogen Idec, Sangamo BioSciences partner to develop therapeutics for hemoglobinopathies

Biogen Idec and Sangamo BioSciences, Inc. announced today an exclusive worldwide collaboration and license agreement focused on the development of therapeutics for hemoglobinopathies, inherited conditions that result from the abnormal structure or underproduction of hemoglobin.

9 Jan 2014

Nottingham scientists exploit MRI technology to assist in the treatment of IBS

Scientists at The University of Nottingham are leading the world in exploiting MRI technology to assist in the treatment and diagnosis of Irritable Bowel Syndrome, a condition that causes serious inconvenience and discomfort to sufferers.

9 Jan 2014

Illumina signs multi-year licensing agreement with Quest Diagnostics

Illumina, Inc. today announced it has entered into a multi-year licensing agreement with Quest Diagnostics, the world's leading provider of diagnostic information services, related to the use of Illumina's next-generation sequencing technology for clinical laboratory testing.

From Illumina, Inc. 9 Jan 2014

ILiAD, Inserm and IPL sign worldwide license agreement for Bordetella pertussis vaccine technology

ILiAD Biotechnologies, LLC, the French National Institute of Health and Medical Research subsidiary, Inserm Transfert SA, and Institut Pasteur de Lille today announced the signing of scientific collaboration and worldwide license agreements for live attenuated Bordetella pertussis vaccine technology, including BPZE1, developed by the laboratory of Professor Camille Locht. This license agreement covers patent rights from Institut Pasteur de Lille, Inserm, National University of Singapore and National University of Ireland Maynooth.

9 Jan 2014

Researchers develop new, safer and noninvasive diagnostic technique for ulcers

Doctors may soon be able to diagnose stomach ulcers without taking tissue samples from the stomach. Researchers from the University of Southern Denmark now report to have developed a new, safer and noninvasive diagnostic technique for ulcers.

8 Jan 2014

Immunocore, MedImmune sign oncology research collaboration and licensing agreement

Immunocore Limited, the Oxford-based biotechnology company developing novel biological drugs to treat cancer and viral disease, today announced that it has entered into an oncology research collaboration and licensing agreement with MedImmune, the global biologics research and development arm of AstraZeneca. Both companies will research and develop novel cancer therapies using Immunocore’s Immune Mobilising Monoclonal T-Cell Receptor Against Cancer technology.

8 Jan 2014

FDA completes inspection of LSNE's medical device manufacturing facility in Manchester

Lyophilization Services of New England, a New Hampshire based contract manufacturing organization is pleased to announce that the Food and Drug Administration recently completed an inspection of their Manchester manufacturing facility.

8 Jan 2014

Apitope-led consortium awarded FP7 Health Innovation funding to develop Graves' disease vaccine

Apitope, the drug discovery and development company focused on treating the underlying cause of autoimmune diseases, today announces that the consortium, led by Apitope, which includes GSK Vaccines, Quintiles and KWS Biotest Limited, has been awarded prestigious Framework Programme 7 Health Innovation funding by the European Commission to develop its Graves' disease therapeutic vaccine, including a Phase I first-in-man study in Graves' disease patients.

8 Jan 2014

Insight Genetics receives $1.5M SBIR contract to research on resistance mutations in NSCLC patients

Insight Genetics, Inc. today announced it has received a new $1.5 million Phase II Small Business Innovation Research contract from the National Cancer Institute.

8 Jan 2014

CytoDyn receives FDA approval to start Phase 2b study of PRO 140 for treatment of HIV-1

CytoDyn Inc., a biotechnology company focused on the development of new therapies for combating infection with immune deficiency viruses, announced today the Company has received approval from the United States Food and Drug Administration (FDA) to commence patient screening of a Phase 2b study of PRO 140, a monoclonal CCR5 antibody, for the treatment of patients with Human Immunodeficiency Virus Type 1.

8 Jan 2014

CROS NT acquires MDSL International

As part of the CROS NT Group global growth strategy, CROS NT Ltd today announced the acquisition of MDSL International - a specialist clinical Contract Research Organization (CRO) providing biometrics services such as Clinical Data Management and Statistical services. The financial details of the transaction remain confidential.

8 Jan 2014

Biothera reports positive results from Phase 2 clinical trial of Imprime PGG in NSCLC patients

Biothera today reported positive results from its proof of concept Phase 2 clinical trial in 90 patients with advanced non-small cell lung cancer (NSCLC) at the American Association for Cancer Research and the International Association for the Study of Lung Cancer joint conference on the Molecular Origins of Lung Cancer in San Diego.

8 Jan 2014

e-Therapeutics announces continuation of ETS2101 phase I trial in brain cancer

e-Therapeutics plc today announces that the investigator-led phase I trial of ETS2101 in brain cancer will continue into 2014. Five dose escalation steps have been completed without any drug-related serious adverse events and the investigator therefore intends to enrol further patients at higher dose levels.

7 Jan 2014

Adocia initiates phase IIa clinical trial of BioChaperone Lispro formulation

Adocia, a biotechnology company specialized in the development of ‘best-in-class’ medicines from already approved therapeutic proteins, in particular proteins and oncologic treatments, launches today a phase IIa clinical trial on its ultra-fast acting formulation of insulin Lispro (Humalog, Eli Lilly) using its proprietary technology BioChaperone).

7 Jan 2014

Researchers work on alternative therapy to boost immune system of patients with lung cancer

Research from the National Institute of Respiratory Diseases informs that besides smoking, there are other factors associated to the development of lung cancer such as the smoke from burning lumber and coal, as well as pollutant particles.

7 Jan 2014

USAMRMC to develop strategic research plan that identifies critical research priority areas in TBI

The U.S. Department of Defense funds more than 500 neurotrauma research projects totaling over $700 million. Yet there remains a large unmet medical need for effective treatments of traumatic brain injury (TBI), a major cause of disability and mortality.

6 Jan 2014

Biotechnology News and Research

Research reveals new therapy for preventing production of sphingolipids by lymphoma cells

Researchers discover two genetic mutations associated with Familial Alzheimer's Disease

Life Technologies, Quest Diagnostics sign multi-year license and supply agreement

Nottingham scientists use MRI technology to assist in treatment, diagnosis of irritable bowel syndrome

Biogen Idec, Sangamo BioSciences partner to develop therapeutics for hemoglobinopathies

Nottingham scientists exploit MRI technology to assist in the treatment of IBS

Illumina signs multi-year licensing agreement with Quest Diagnostics

ILiAD, Inserm and IPL sign worldwide license agreement for Bordetella pertussis vaccine technology

Researchers develop new, safer and noninvasive diagnostic technique for ulcers

Immunocore, MedImmune sign oncology research collaboration and licensing agreement

FDA completes inspection of LSNE's medical device manufacturing facility in Manchester

Apitope-led consortium awarded FP7 Health Innovation funding to develop Graves' disease vaccine

Insight Genetics receives $1.5M SBIR contract to research on resistance mutations in NSCLC patients

CytoDyn receives FDA approval to start Phase 2b study of PRO 140 for treatment of HIV-1

CROS NT acquires MDSL International

Biothera reports positive results from Phase 2 clinical trial of Imprime PGG in NSCLC patients

e-Therapeutics announces continuation of ETS2101 phase I trial in brain cancer

Adocia initiates phase IIa clinical trial of BioChaperone Lispro formulation

Researchers work on alternative therapy to boost immune system of patients with lung cancer

USAMRMC to develop strategic research plan that identifies critical research priority areas in TBI

Event guide: 3rd IMPACCT Real World Evidence Summit Europe eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News